Difference between revisions of "Defibrotide (Defitelio)"
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m (Text replacement - "[[Media:" to "[[File:") |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Profibrinolytic. Defibrotide is a mixture of polydeoxyribonucleotide sodium salts made from porcine intestinal tissue. In vitro, it boosts enzymatic activity of plasmin to hydrolyze fibrin clots. Defibrotide increases tissue plasminogen activator (t-PA) and thrombomodulin expression while decreasing von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1) expression. Endothelial cell fibrinolysis is enchanced and endothelial cell activation is reduced. Defibrotide appears to limit damage caused by chemotherapy, tumor necrosis factor-α (TNF-α), serum starvation, and perfusion.<ref name=insert>[http://defitelio.com/DefitelioPI.pdf Defibrotide (Defitelio) package insert]</ref><ref>[[ | + | Class/mechanism: Profibrinolytic. Defibrotide is a mixture of polydeoxyribonucleotide sodium salts made from porcine intestinal tissue. In vitro, it boosts enzymatic activity of plasmin to hydrolyze fibrin clots. Defibrotide increases tissue plasminogen activator (t-PA) and thrombomodulin expression while decreasing von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1) expression. Endothelial cell fibrinolysis is enchanced and endothelial cell activation is reduced. Defibrotide appears to limit damage caused by chemotherapy, tumor necrosis factor-α (TNF-α), serum starvation, and perfusion.<ref name=insert>[http://defitelio.com/DefitelioPI.pdf Defibrotide (Defitelio) package insert]</ref><ref>[[File:Defibrotide.pdf|Defibrotide (Defitelio) package insert (locally hosted backup)]]</ref><ref>[http://defitelio.com/ Defitelio manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
Revision as of 00:25, 20 September 2021
General information
Class/mechanism: Profibrinolytic. Defibrotide is a mixture of polydeoxyribonucleotide sodium salts made from porcine intestinal tissue. In vitro, it boosts enzymatic activity of plasmin to hydrolyze fibrin clots. Defibrotide increases tissue plasminogen activator (t-PA) and thrombomodulin expression while decreasing von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1) expression. Endothelial cell fibrinolysis is enchanced and endothelial cell activation is reduced. Defibrotide appears to limit damage caused by chemotherapy, tumor necrosis factor-α (TNF-α), serum starvation, and perfusion.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Hepatic veno-occlusive disease (VOD), sinusoidal obstructive syndrome (SOS) with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).
Patient drug information
- Brief patient counseling information available in the Defibrotide (Defitelio) package insert[1]
History of changes in FDA indication
- 3/30/2016: FDA approved "for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstructive syndrome, with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT)."
Also known as
- Generic name: polydeoxyribonucleotide sodium salt
- Brand name: Defitelio